Trial
NCT04186247
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Crohn's and Colitis Foundation; University of Amsterdam; OM Pharma SA
Condition
Crohn Disease
Intervention
Azithromycin
Why stopped
The DSMB concluded that feasibility endpoints were reached in time for Week 4 but no participants receiving standard of care dietary treatment could be randomized based on the at-risk of the microbiome signature.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-29